Companies › Cartography Biosciences
1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Apr 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CBI-1214 Bispecific T cell engager targeting LY6G6D on colorectal cancer cells and CD3 on T cells | LY6G6D, CD3 | Phase 1 | Colorectal Cancer | Apr 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07321106 | CBI-1214 | Phase 1 | Colorectal Cancer | Oncology | Apr 2029 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.